Genoway Interest Expense
The Interest Expense of Genoway (ALGEN.PA) as of Oct 10, 2026 is 443,000.00 EUR. In the previous year, Interest Expense was -73,500.00 EUR — a change of -702.72% (higher).
Get this data via API
Financial Data API
Interest Expense
443,000.00EUR
YoY
-702.72%
Last updated:
Interest Expense of Genoway is 2024 443,000.00 EUR. Interest Expense of Genoway was 2023 -73,500.00 EUR. It decreases by -702.72% higher compared to the previous year.
The Genoway Interest Expense history
3 Years
10 Years
25 Years
Max
Interest Expense
Date
Interest Expense
Jan 1, 2017
-153,800.00 EUR
Jan 1, 2018
-169,400.00 EUR
Jan 1, 2019
-119,200.00 EUR
Jan 1, 2020
-86,200.00 EUR
Jan 1, 2021
-112,000.00 EUR
Jan 1, 2022
-118,500.00 EUR
Jan 1, 2023
-73,500.00 EUR
Jan 1, 2024
443,000.00 EUR
| YEAR | Interest Expense | YoY |
|---|---|---|
| 443,000.00EUR | -702.72% | |
| -73,500.00EUR | -37.97% | |
| -118,500.00EUR | +5.80% | |
| -112,000.00EUR | +29.93% | |
| -86,200.00EUR | -27.68% | |
| -119,200.00EUR | -29.63% | |
| -169,400.00EUR | +10.14% | |
| -153,800.00EUR | -789.69% | |
| 22,300.00EUR | -111.93% | |
| -186,900.00EUR | +102.49% | |
| -92,300.00EUR | — |
Access this data via the Eulerpool API
Genoway Stock analysis
What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies.
The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression.
Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo.
Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry.
Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells.
In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues.
Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genoway stock
Interest Expense of Genoway is 443,000.00 EUR in 2024.
Interest Expense of Genoway changed from -73,500.00 EUR to 443,000.00 EUR, representing a -702.72% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Interest Expense Genoway since 2006 – with annual values, charts, and detailed analysis.
Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.
Interest Expense's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Genoway historically and in real time.
Access this data via the Eulerpool API
Income Statement — Genoway
All Key Metrics — Genoway
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth